122647-32-9

122647-32-9 structure
122647-32-9 structure
  • Name: Ibutilide fumarate
  • Chemical Name: Ibutilide Hemifumarate
  • CAS Number: 122647-32-9
  • Molecular Formula: C22H38N2O5S
  • Molecular Weight: 442.61
  • Catalog: Biochemical Inhibitor Transmembrane Transporters Sodium Channel inhibitor
  • Create Date: 2018-03-10 08:00:00
  • Modify Date: 2025-08-20 11:29:07
  • Ibutilide Fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.Target: Calcium ChannelIbutilide is the first 'pure' class III antiarrhythmic drug to become available. Its predominant action is prolongation of the myocardial action potential duration. Intravenous ibutilide 0.01 to 0.025 mg/kg or 1 to 2 mg successfully converted atrial flutter or fibrillation to sinus rhythm in 33 to 49% of patients in 2 placebo-controlled trials involving 439 patients with sustained arrhythmia [1]. Ibutilide appears to be an effective alternative method for rapid conversion of recent-onset AF or AFl. The drug may be particularly useful in patients who have undergone recent cardiac surgery or those who are not ideal candidates for DCC [2].

Name Ibutilide Hemifumarate
Synonyms N-(4-{4-[Ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide (2E)-but-2-enedioate (2:1)
(±)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-2-butenedioate (2:1) (Salt)
Bis[N-ethyl-N-(4-hydroxy-4-{4-[(methylsulfonyl)amino]phenyl}butyl)heptan-1-aminium] (2E)-but-2-enedioate
N-(4-{4-[Ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide (2E)-2-butenedioate (2:1)
Methanesulfonamide, N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]-, (2E)-2-butenedioate (2:1) (salt)
Bis[N-ethyl-N-(4-hydroxy-4-{4-[(methylsulfonyl)amino]phenyl}butyl)heptan-1-aminium]-(2E)-but-2-endioat
(±)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-Butenedioate (2:1)
N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide (2E)-but-2-enedioate (2:1) (salt)
Bis[N-ethyl-N-(4-hydroxy-4-{4-[(methylsulfonyl)amino]phenyl}butyl)-1-heptanaminium] (2E)-2-butenedioate
Ibutilide hemifumarate salt
Ibutilide fumarate
UNII:9L5X4M5L6I
(2E)-But-2-endisäure--N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methansulfonamid(1:2)
acide (2E)-but-2-ènedioïque - N-(4-{4-[éthyl(heptyl)amino]-1-hydroxybutyl}phényl)méthanesulfonamide (1:2)
Corvert
Ibutilide (fumarate)
Description Ibutilide Fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.Target: Calcium ChannelIbutilide is the first 'pure' class III antiarrhythmic drug to become available. Its predominant action is prolongation of the myocardial action potential duration. Intravenous ibutilide 0.01 to 0.025 mg/kg or 1 to 2 mg successfully converted atrial flutter or fibrillation to sinus rhythm in 33 to 49% of patients in 2 placebo-controlled trials involving 439 patients with sustained arrhythmia [1]. Ibutilide appears to be an effective alternative method for rapid conversion of recent-onset AF or AFl. The drug may be particularly useful in patients who have undergone recent cardiac surgery or those who are not ideal candidates for DCC [2].
Related Catalog
References

[1]. Foster, R.H., M.I. Wilde, and A. Markham, Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs, 1997. 54(2): p. 312-30.

[2]. Howard, P.A., Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother, 1999. 33(1): p. 38-47.

Boiling Point 522.4ºC at 760 mmHg
Melting Point 112-117?C
Molecular Formula C22H38N2O5S
Molecular Weight 442.61
Flash Point 269.7ºC
PSA 230.64000
LogP 10.34740
Vapour Pressure 9.71E-12mmHg at 25°C
Storage condition Refrigerator

CHEMICAL IDENTIFICATION

RTECS NUMBER :
PB0475700
CAS REGISTRY NUMBER :
122647-32-9
LAST UPDATED :
199712
DATA ITEMS CITED :
5
MOLECULAR FORMULA :
C40-H72-N4-O6-S2.C4-H4-O4
MOLECULAR WEIGHT :
885.36

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD - Lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 49,406,1994
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
94200 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 49,406,1994 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 54,157,1996
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 54,157,1996
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
200 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 54,157,1996
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H302
Precautionary Statements P301 + P312 + P330
Hazard Codes Xn
Risk Phrases 22
RIDADR NONH for all modes of transport
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.